Cogent Biosciences Inc
COGTHealthcare|Biotechnology|USA
$38.87
-1.62 (-4.00%)
Tangible Book
$3.18
Earnings Power
$4.21
About
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Stock Price
+258.2%(1Y)
Pipeline Summary
17 total trials8
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
Active: 3Recruiting: 5Terminated: 4Completed: 2AVAILABLE: 2Unknown: 1
Active Trials (8)
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
NCT05186753SSM
Phase 2Active
Enrollment: 237 participants
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875Advanced Systemic Mastocytosis (AdvSM)
Phase 2Recruiting
Enrollment: 140 participants
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations
Phase 1Recruiting
Enrollment: 90 participants
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05208047Advanced Gastrointestinal Stromal Tumors
Phase 3Recruiting
Enrollment: 482 participants
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562Advanced Solid Tumor, Adult
Phase 1Recruiting
Enrollment: 100 participants
BioScore
5.1/10
Watchlist
Ownership
Recent Insider Trades
Fairmount Funds Management LLCSELL
2026-03-317,000,000 shares @ $34.66
Fairmount Funds Management LLCSELL
2026-01-223,500,000 shares @ $36.4
Sachs JessicaSELL
2025-12-2682,642 shares @ $38.7
Green John L.SELL
2025-12-2677,000 shares @ $38.68
Robinson John EdwardSELL
2025-12-2690,000 shares @ $38.74
Recent News
2026-06-30 12:27:53
Data last updated: Jul 12, 2026, 07:41 PM